Aurinia Pharmaceuticals Inc (AUPH) News

Form 8-K - Current report

Aurinia Announces Board Restructuring

Peter Greenleaf, President and Chief Executive Officer of Aurinia, remains a Director Kevin Tang, President of Tang Capital Management, LLC...

Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announced today that the first participant has been dosed in a Phase 1a...

Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the H.C...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results

Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing...

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for...

Aurinia to Participate in Upcoming Investor Healthcare Conferences

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will participate in...

Form 8-K - Current report

Aurinia Announces 2024 Annual General Meeting Results

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced voting results for its 2024 annual general meeting (the...

Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced an oral presentation at the European Alliance of...

Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce

Raises Concerns Surrounding Lucien Selce's Self-Serving Proposals and Lack of Credibility Glass Lewis Recommends that Aurinia Shareholders Vote...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material